Clinical trials: Rhinovirus
Healthy Volunteers and Asthma
A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16
The main purposes of this study are to evaluate the safety (Parts 1 and 2) and efficacy (Part 2) of pretreatment with CNTO 3157 in healthy adult and asthmatic adult participants before and after intranasal (into the nose)…
- Trial name
- NCT01704040
- Testing
- CNTO 3157 (healthy participants), CNTO 3157 (asthmatic patients), HRV-16
- Where
- 13 sites in Belgium, Canada and 4 more
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Asthma
Study Of RV-39 In Patients Who Also Have Asthma
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum…
- Trial name
- NCT00503009
- Testing
- fluticasone propionate/salmeterol, fluticasone propionate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Common Cold, Viral Infection
Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses
Coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. The goal of the study is to determine whether the iota-carrageenan content in the saliva of subjects who sucked Coldamaris® lozenges is sufficient to…
- Trial name
- NCT04533906
- Testing
- Coldamaris lozenges
- Where
- Austria
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Marinomed Biotech AG
Rhinovirus Infection
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV…
- Trial name
- Cardinal COPD (NCT07610395)
- Testing
- VPV 1000 mg, VPV 500 mg
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 180 people
- Sponsor
- Altesa Biosciences, Inc.
GBM, Glioblastoma
PVSRIPO for Recurrent Glioblastoma (GBM)
Purpose of the Study: To determine the maximally tolerated dose (MTD) and the Recommended Phase 2 Dose (RP2D) of PVSRIPO when delivered intracerebrally by convection-enhanced delivery (CED).
- Conditions
- GBM, Glioblastoma, Glioma, Malignant Glioma
- Trial name
- PVSRIPO (NCT01491893)
- Testing
- Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Istari Oncology, Inc.
QIAGEN ResPlex II Advanced Panel, Influenza A
Collection and Testing of Respiratory Samples
The study will be conducted using nasopharyngeal swab specimens collected prospectively from individuals suspected of having the signs and symptoms of an acute respiratory tract infection caused by a respiratory virus.
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1
- Trial name
- NCT01302418
- Testing
- artus Influenza A/B RT-PCR Test
- Where
- 5 sites in United States
- Volunteers
- 272 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Respiratory Tract Infections [C08.730]
Rhinovirus Study With Lactobacillus Rhamnosus GG
The purpose of this study is to evaluate the symptom impact of probiotic Lactobacillus rhamnosus GG during rhinovirus infection.
- Trial name
- NCT01229917
- Testing
- Fruit juice with Lactobacillus rhamnosus GG, version 1, Fruit juice with Lactobacillus rhamnosus GG, version 2, Standard fruit juice
- Where
- United States
- Sponsor
- Valio Ltd
Enterovirus, Rhinovirus
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
- Trial name
- NCT03605862
- Testing
- Nitazoxanide
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 1,756 people
- Sponsor
- Romark Laboratories L.C.
Common Cold
Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold
This study evaluates the performance of ColdZyme® mouth spray on prevention and alleviation of induced rhinovirus upper respiratory tract infection in healthy volunteers.
- Trial name
- COLDPREV (NCT02522949)
- Testing
- ColdZyme® mouth spray
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Enzymatica AB
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma
This is a Phase 1b, single center study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3923868 following repeat doses in mild asthmatics during experimental human…
- Trial name
- NCT05398198
- Testing
- GSK3923868
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Acute Nasopharyngitis
Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers
2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy volunteers (NHV).
- Trial name
- NCT05314933
- Testing
- 2-Deoxyglucose
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- G.ST Antivirals GmbH
Rhinovirus
A Study of APL-10456-Vaccine
AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of…
- Trial name
- NCT07399132
- Testing
- APL-10456-Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Apollo Therapeutics Ltd
Rhinovirus
Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge
A GMP rhinovirus was manufactured according to GMP and then characterised in human volunteers in the human viral challenge model.
- Trial name
- NCT02522832
- Testing
- Titre 1, Titre 2, Titre 3
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hvivo
Asthma
Study Examining PrEP-001 in Subjects With Asthma
Phase 2 study, to examine the prophylactic efficacy, safety and tolerability of PrEP-001 in asthmatics who have been infected with the human rhinovirus (HRV16) after receiving two doses of the study drug/placebo.
- Trial name
- NCT03296917
- Testing
- PrEP-001, G-004
- Volunteers
- 60 people
- Sponsor
- Hvivo